3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
7
Small Cell Lung Carcinoma
6
Fallopian Tube Neoplasms
4
Lung Neoplasms
3
Sarcoma, Ewing
2
Neoplasm Metastasis
2
Ganglioneuroblastoma
2
Uterine Cervical Neoplasms
1
SCLC
1
Rhabdoid Tumor
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Fallopian Tube Mucinous Adenocarcinoma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Interventions
Nivolumab
21
pembrolizumab
19
Ipilimumab
14
Specimen Handling
12
Magnetic Resonance Spectroscopy
7
Opdualag
6
CTLA-4 Antigen
6
relatlimab
5
binimetinib
5
trametinib
4
Paclitaxel
4
dabrafenib
3
Taxes
3
Standard of Care
3
Pemetrexed
3
Introns
3
Interferon alpha-2
3
Gemcitabine
3
Carboplatin
3
Blood Specimen Collection
3
ulixertinib
2
sargramostim
2
lifileucel
2
lenvatinib
2
fludarabine phosphate
2
fludarabine
2
encorafenib
2
capivasertib
2
cabozantinib
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Melanoma
×
Topotecan
×
30 days
×
Clear all
No trials found.